Lemaitre Vascular (LMAT) Liabilities and Shareholders Equity (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $629.5 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $629.5 million, up 13.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 31.0% YoY), and the FY2025 annual result was $615.7 million, up 11.58% from the prior year.
• Liabilities and Shareholders Equity climbed to $629.5 million in Q1 2026 per LMAT's latest filing, from $615.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $629.5 million in Q1 2026 and troughed at $292.5 million in Q1 2022.
• A 5-year average of $420.5 million and a median of $354.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity increased 4.34% in 2022, then jumped 59.13% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $310.5 million in 2022, then advanced by 11.69% to $346.8 million in 2023, then jumped by 59.13% to $551.8 million in 2024, then gained by 11.58% to $615.7 million in 2025, then gained by 2.25% to $629.5 million in 2026.
• Business Quant data shows LMAT's Liabilities and Shareholders Equity at $629.5 million in Q1 2026, $615.7 million in Q4 2025, and $598.1 million in Q3 2025.